Unison Pharmaceuticals Appoints Prasad Mahajan as General Manager for Quality and Manufacturing
Unison Pharmaceuticals appoints Prasad Mahajan as General Manager, consolidating quality control and regulatory compliance under senior leadership.

Unison Pharmaceuticals has placed regulatory compliance expertise at the GM level, a structural signal that Indian mid-tier manufacturers are embedding quality leadership deeper into their operational hierarchies. Prasad Mahajan steps into the General Manager role with a remit that spans quality control, regulatory compliance, and operational excellence across manufacturing and quality functions.
The scope of the appointment reflects a broader pattern visible across Indian pharmaceutical manufacturers: compliance accountability is migrating upward from QA department heads toward cross-functional general management. For plant heads and QA directors, that shift carries direct implications for how CAPA ownership, deviation management, and process validation governance are structured at the site level.
Mahajan's mandate to strengthen regulatory compliance arrives at a point when Indian manufacturers face sustained scrutiny from agencies including the USFDA and MHRA, with inspection cadences returning to pre-pandemic frequency. Operational excellence programs tied to GMP frameworks such as ICH Q10 increasingly require a single accountable leader who can bridge shop-floor execution and regulatory documentation, precisely the profile a GM-level quality appointment is designed to fill.
For regulatory affairs leads tracking workforce trends, the Unison move adds to a growing dataset of Indian manufacturers consolidating quality and manufacturing oversight under unified senior leadership, rather than maintaining siloed functional heads reporting independently to a site director.
How Mahajan translates the operational excellence mandate into measurable quality metrics, batch right-first-time rates, OOS reduction, inspection readiness scores, will serve as an early indicator of whether the structural elevation of compliance leadership at Unison produces the outcomes the appointment implies.
Source: Media4Growth via Indian Pharma Post, 9 August 2026.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
Innate Pharma Signs USD 580M Lacutamab Deal with Sobi to Fund CTCL Phase 3 Trial

Gland Pharma Secures Global CDMO Deal Targeting $100 Million in Annual Injectable Revenue

Discussion